Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clobenpropit SCHEMBL8312286 | 0.96 | HRH4 (0.40) | HRH4HRH3KMT2APKMHRH2 | |
| Clobenpropit SCHEMBL15130115 | 0.95 | HRH4 (0.42) | HRH4HRH3KMT2APKMHRH2 | |
| SCHEMBL16840342 | 0.85 | SMN1; SMN2 (0.38) | HRH4HRH3KMT2AMAPTQPCT | |
| SCHEMBL11659295 | 0.82 | IDO1 (0.38) | HRH4HRH3KMT2AHRH2MEN1 | |
| SCHEMBL8624151 | 0.79 | NOS1 (0.39) | KMT2AMEN1IDO1POLBMAPT | |
| SCHEMBL9079252 | 0.76 | PLAAT3 (0.40) | KMT2APKMMEN1LMNAPOLB | |
| SCHEMBL9081222 | 0.76 | KMT2A (0.37) | HRH4KMT2APKMHRH2MEN1 | |
| SCHEMBL9029336 | 0.76 | POLB (0.40) | KMT2APKMMEN1LMNAPOLB | |
| Iodophenpropit SCHEMBL13039517 | 0.76 | HRH4 (0.35) | HRH4HRH3KMT2AMEN1 | |
| SCHEMBL7974343 | 0.75 | HRH4 (0.51) | HRH4HRH3KMT2APKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035380-A1 | INHIBITION OF GLIAL CELL ACTIVATION | LAPKO INC DBA AFECTA PHARMACEUTICALS (US) | 2026-02-05 | — | — | US | disclosed |
| US-11858876-B2 | CCL2 inhibitors | LAPKO INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11628154-B2 | CCL5 inhibitors | LAPKO INC (US) | 2023-04-18 | — | — | US | disclosed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-11497724-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220202796-A1 | CXCL10 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-06-30 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628154-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | HRH4 1312/4885HRH3 1613/4885KMT2A 4842/4885 |
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | HRH4 1312/4885HRH3 1613/4885KMT2A 4842/4885 |
| US-20260035380-A1 | INHIBITION OF GLIAL CELL ACTIVATION | CHAT, CCRL2, PMP22 | HRH4 90/4885HRH3 40/4885KMT2A 2572/4885 |
| US-11497724-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | HRH4 1312/4885HRH3 1613/4885KMT2A 4842/4885 |
| US-20220202796-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | HRH4 2949/4885HRH3 2493/4885KMT2A 3380/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | HRH4 1312/4885HRH3 1613/4885KMT2A 4842/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | HRH4 1312/4885HRH3 1613/4885KMT2A 4842/4885 |
| US-11858876-B2 | CCL2 inhibitors | CCL2, CCL11, CCR2 | HRH4 1472/4885HRH3 720/4885KMT2A 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.